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Abstract: The effects of an intermittent fasting diet (IFD) in the general population are still controversial.
In this study, we aimed to systematically evaluate the effectiveness of an IFD to reduce body mass index
and glucose metabolism in the general population without diabetes mellitus. Cochrane, PubMed,
and Embase databases were searched to identify randomized controlled trials and controlled clinical
trials that compared an IFD with a regular diet or a continuous calorie restriction diet. The effectiveness
of an IFD was estimated by the weighted mean difference (WMD) for several variables associated with
glucometabolic parameters including body mass index (BMI) and fasting glucose. The pooled mean
differences of outcomes were calculated using a random effects model. From 2814 studies identified
through a literature search, we finally selected 12 articles (545 participants). Compared with a control
diet, an IFD was associated with a significant decline in BMI (WMD, −0.75 kg/m2; 95% CI, −1.44 to
−0.06), fasting glucose level (WMD, −4.16 mg/dL; 95% CI, −6.92 to −1.40), and homeostatic model
assessment of insulin resistance (WMD, −0.54; 95% CI, −1.05 to −0.03). Fat mass (WMD, −0.98 kg;
95% CI, −2.32 to 0.36) tended to decrease in the IFD group with a significant increase in adiponectin
(WMD, 1008.9 ng/mL; 95% CI, 140.5 to 1877.3) and a decrease in leptin (WMD, −0.51 ng/mL; 95% CI,
−0.77 to −0.24) levels. An IFD may provide a significant metabolic benefit by improving glycemic
control, insulin resistance, and adipokine concentration with a reduction of BMI in adults.
Keywords: intermittent fasting; glucose metabolism; insulin resistance; body mass index
1. Introduction
Calorie restriction (CR) is known not only to reduce body weight but also to improve various
cardiovascular risk factors [1]. Prolonged CR has been shown to reduce fat mass with significant
weight loss. An improvement of insulin resistance was also identified after CR [2]. Mechanisms
of CR-mediated improvement of glucose metabolism are not fully elucidated, but possibly involve
significant alterations in insulin sensitivity of skeletal muscle [3], along with the reduction of fat mass.
Nevertheless, there are many difficulties in sustaining daily CR [4]. As an alternative diet
intervention to CR, weight control through intermittent fasting (IF) has been proposed. A variety of
diets have been used to study the effects of IF [5], including alternate-day fasting (ADF, consuming no
calories on fasting days) [6], alternate-day modified fasting (ADMF, consuming less than 25% of baseline
energy needs on fasting days) [7,8], time-restricted fasting (TRF, restricting food intake to specific time
periods of the day) [9], and periodic fasting (PF, fasting only one to two day per week) [10]. In addition
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to the effect on weight loss, many studies have shown that through IF we can expect a powerful effect
on improvement of glucose metabolism by lowering insulin resistance [11], improvement of systemic
inflammatory diseases [12–15], protection against neurodegeneration, and even expansion of the life
span [16].
In a recent study, an IF diet (IFD) improved insulin sensitivity even when the supplied calories
were the same as those of the control group, without significant change in body weight [17]. This
shows that IF, itself, can be beneficial to glucose metabolism independent of body weight changes,
however, contrary to other results, in some controlled, randomized crossover trials, IF did not improve
glucose and lipid metabolism [18,19]. Likewise, there were also conflicting results in the effect of
weight reduction. Although some studies reported significant weight reduction in an IFD group [7,20],
several other trials did not report a clinically meaningful weight reduction [18,21].
As seen from the varied and inconsistent findings of previous studies, many hurdles based on
the characteristics of the diet intervention study, such as non-standardized dietary control of the
patient, low compliance, and the number of participants due to the difficulty of conducting a study
covering an entire period, and the difficulty of setting the control group, make it difficult to identify the
beneficial effects of an IFD. Furthermore, several previous meta-analysis studies on the glucometabolic
effect of an IFD have also shown conflicting results [22,23], which is important for establishing diet
recommendations for the general population including the population with obesity or prediabetes.
Thus, this study aimed to investigate the effectiveness of IF on weight loss and glucose metabolism by
analyzing the effect size of previous studies among the general population without diabetes mellitus
(DM).
2. Experimental Section
2.1. Data Sources and Search Strategies
We searched articles using Cochrane (from inception to Nov 2018), PubMed (from inception to Nov
2018), and Embase (from inception to Nov 2018) published before November 15, 2018. The terms used in
the literature search were “intermittent fasting,” “Ramadan diet”, “Ramadan fasting”, “time-restricted
fasting”, “time-restricted feeding”, “alternate fasting”, “periodic fasting”, “periodic diet”, “reduced
meal frequency”, “alternate-day fasting” and “alternate-day modified fasting” for intervention terms.
These search terms were combined with “OR”. In addition, “normal human”, “adult”, “patient”,
“human”, “obesity”, “diabetes mellitus”, “diabetes”, “metabolic syndrome” and “obese” were also
combined with “OR” as terms for the objects. The abovementioned two term groups were combined
with “AND”. Languages were limited to English. This study was registered before the data analysis
(Prospero CRD42019125120). This was a literature-based descriptive study, and therefore approval by
the institutional review board or informed consent was not required.
2.2. Eligibility Criteria
The inclusion criteria of the literature were as follows: studies on the general population without
chronic diseases that could affect glucose metabolism including diabetes mellitus (patients, P); those
that studied an IFD (intervention, I); those that compared the control groups, regular diet (RD) or
continuous CR diet control without fasting (≥12 h) (comparison, C); and those that described fasting
glucose, homeostatic model assessment of insulin resistance (HOMA-IR), total body weight, body
mass index (BMI), lean mass, fat mass, leptin, and adiponectin (outcome, O) according to the research
question (PICO). Only controlled trials of supervised diet programs were eligible. Studies were limited
to interventions which were a minimum 4 weeks in duration. In addition, only studies that presented
the mean and standard deviation of the results were selected.
We excluded studies on patients with diabetes mellitus, chronic liver disease, chronic renal disease,
and studies on pregnancy (P); those that involved a combination with specific nutrient restriction diet
intervention (I); those that compared with a different type of IFD (C); and those with results other
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than the parameter of glucose metabolism, such as psychological parameter (O). The literature was
independently selected by two researchers (Namki Hong and Yongin Cho), and cases of inconsistencies
were resolved via a thorough discussion. In consideration of the possibility that some articles could be
missed by the above search terms, we further searched the review papers of similar topics to see if
there were any papers corresponding to the same PICO. 2.3. Data Extraction
Fasting glucose, HOMA-IR, BMI, fat mass, lean mass, leptin, adiponectin, and total body weight
were used as variables for the effect of an IFD and were calculated using the mean, standard deviation,
number of participants, as well as baseline and final values. The contents of the literature were
examined in detail, and the types of IFD and control diet were coded and presented. If there was a
numerical result due to the different control group in the contents of one document, the data were
extracted according to categories for the control group and errors resulting from the duplication of the
same documents were supplemented using statistical techniques.
2.3. Statistical Analysis
To supplement the systematic review, a meta-analysis was performed. STATA 15 (StataCorp
LLC, College Station, TX, USA) was used to synthesize the effect sizes of the 12 selected documents.
The weighted mean difference (WMD) between the baseline and final measurements of fasting glucose,
HOMA-IR, BMI, fat mass, lean mass, leptin, adiponectin, and total body weight according to the
intervention were considered as the effect size, and the inverse variance method was used because
the values were continuous variables. The random effects model was chosen because of the diversity
and heterogeneity of the intervention. Heterogeneity was estimated using the I2 statistic across the
studies [24]. I2 values were interpreted as follows: 0% to 40%, no important heterogeneity; 30% to 60%,
moderate; 50% to 90%, substantial; and 75% to 100%, considerable heterogeneity. The heterogeneity of
pooled effects between subgroups was calculated using the Cochran Q statistic. A funnel plot method
was used to test potential publication bias.
3. Results
3.1. Search Results and Study Characteristics
A total of 2814 studies were selected according to the search method of our study. After eliminating
1216 duplicate documents, the titles and abstracts of 1598 studies were reviewed, and 1097 papers that
had no relevance with the original review according to the PICO were excluded. Among 501 studies
selected by reviewing the titles and abstracts, 12 studies were finally included in this study (Figure 1).
The total number of participants was 545 (261 in the intervention group and 284 in the control group;
210 or 38.5% men and 335 or 61.5% women). The general characteristics of the included studies are
summarized in Table 1.
Figure 1. Flowchart of the study selection.
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Table 1. Characteristics of the studies included in the meta-analysis.
Author Year Design Duration(wk) Intervention Intervention Detail
Fasting
Time of
Intervention
Group (h)
Calorie
Reduction
(From
Baseline, %)
Control
(Without
Fasting)
Control
Detail
Calorie
Reduction
(From
Baseline, %)
Trepanowski et al.
1 [8] 2018
66 women, 13
men (aged
18–65 y,
overweight to
obese, BMI
25–40 kg/m2)
24 ADMF
alternating every 24
h between
consuming 25% or
125% of energy
needs
24 21.0 RD
consuming
100% of
needs every
day
Not shown
Trepanowski et al.
2 [8] 2018
66 women, 13
men (aged
18–65 y,
overweight to
obese, BMI
25–40 kg/m2)
24 ADMF
alternating every 24
h between
consuming 25% or
125% of energy
needs
24 21.0 CR
Consuming
75% of
needs every
day
24.0
Catenacci et al.
[6] 2016
19 women, 6
men (aged
18–55 y, obese,
BMI over
30 kg/m2)
8 ADF
fast on alternate
days, fasting day, at
libitum
24 47.0 CR
400 kcal/d
deficit from
estimated
energy
requirements
28.0
Gabel et al. [9] 2018
41 women, 5
men (aged
25–65 y, obese,
BMI
30–45 kg/m2)
12 TRF
ad libitum feeding
between 10 am to
6pm, fasting
between 6pm to
10am
16 20.3 RD
not to
change their
eating or
physical
activity
habits
Not shown
Moro et al. [25] 2016
34 men (aged
29.21 ± 3.8 y,
weighted 84.6
± 6.2 kg)
8 TRF + Ex 1 p.m., 4 p.m., 8p.m. feeding 16 3.2
RD +
Ex
8 a.m., 1
p.m., 8 p.m.
feeding
Not shown
Bhutani et al. 1
[20] 2013
80 women, 3
men (aged
25–65 y, obese,
BMI
30–39.9 kg/m2)
12 ADMF
25% of their
baseline energy
needs on the fast
day (24 h), ad
libitum on feed day,
12 p.m. to 2 p.m.
meals on fast day, 3
days/wk
22
Not shown
(450 kcal/d
reduction)
RD
maintain
regular food
habits
Not shown
Bhutani et al. 2
[20] 2013
80 women, 3
men (aged
25–65 y, obese,
BMI
30–39.9 kg/m2)
12 ADMF + Ex
25% of their
baseline energy
needs on the fast
day (24 h), ad
libitum on feed day,
12 p.m. to 2 p.m.
meals on fast day, 3
days/wk
22
Not shown
(450 kcal/d
reduction)
RD +
Ex
maintain
regular food
habits + Ex
Not shown
Teng et al. [26] 2013
56 men (aged
50–70 y, BMI
23–29.9 kg/m2)
12 TRF(periodic)
reduction of
300–500 kcal/d from
participants
baseline energy
intake combined
with two days of
Muslim Sunnah
fasting per weeks
13,
approximately 19.2 RD
maintain
regular food
habits
Not shown
Alsubheen et al.
[27] 2017 16 men 4 TRF Muslim Ramadan 13 16.0 RD
maintain
regular food
habits
7.8
Bouhlel et al.
[28] 2013
20 men (aged
20 y) 4 TRF Muslim Ramadan
Muslim
Sunnah
fasting
10.9 RD
maintain
regular food
habits
Not shown
Hussin et al.
[29] 2013
31 men (aged
50–70 y, BMI
23–29.9 kg/m2)
12 TRF(periodic)
reduction of
300–500 kcal/d from
participants
baseline energy
intake combined
with two days of
Muslim Sunnah
fasting per week
Muslim
Sunnah
fasting
10.3 RD
maintain
regular food
habits
Not shown
Harvie et al.
[10] 2011
107 women
(aged 30–45 y) 24 PF
VLCD for 2 days
per week unknown 29.7 CR
25%
restriction 20.4
Tinsley et al.
[21] 2017 18 men 8
TRF
(periodic) +
Ex
On non-workout
days (four days per
week), consume all
calories in any four
hour window
between 4 p.m. and
midnight /
unrestricted on RT
day
20 13.8 RD +Ex RT 20.3
Varady et al.
[30] 2013
22 women, 8
men (aged
35–63 y, BMI
20–29.9 kg/m2)
12 ADMF
25% of their
baseline energy
needs on the fast
day (24 h), ad
libitum on feed day,
12 p.m. to 2 p.m.
meals on fast day
22 38.0 RD Ad libitum Not shown
3.2. Effectiveness of Intermittent Fasting on BMI and Body Weight
A total of eight studies reported on the effects of an IFD on BMI. Seven studies assessed diet
intervention only, and one of the studies assessed diet intervention with exercise, which was equally
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assessed in the control group. No difference was observed between the two groups for BMI at baseline
(WMD, 0.10 kg/m2; 95% CI, −0.59 to 0.78; p = 0.783). After the diet intervention, BMI was significantly
lower in the IFD group by 0.75 kg/m2 (95% CI, −1.44 to −0.06; p = 0.033; Figure 2). The IFD was also
associated with a trend towards reducing body weight. A total of 10 studies reported on the effects of
an IFD on body weight. All details of the changes in body weight were presented in kilograms (kg).
No difference in body weight at baseline was observed between the two groups (WMD, 0.24 kg; 95%
CI, −3.18 to 3.66; p = 0.889). The weight of the participants was lower in the IFD group by 1.94 kg (95%
CI, −5.20 to 1.31; p = 0.241), without statistical significance (Supplementary Figure S1).
Figure 2. Effect of intermittent fasting (IF) versus a non-fasting control on body mass index (changes
from baseline) in adults without chronic metabolic disease. The squares indicate the study-specific
outcome estimates, and the size of the squares corresponds to the study’s weight in the meta-analysis.
Horizontal lines denote the range of the 95% confidence interval. The diamonds indicate pooled
estimates. Weights are from random effects analysis.
3.3. Effectiveness of Intermittent Fasting on Glycemic Control
A total of eight studies reported on the effectiveness of an IFD to reduce fasting glucose levels. Six
studies assessed an IFD only, and two other studies assessed an IFD with exercise. No difference was
observed between the two groups in fasting glucose at baseline (WMD, −0.64 mg/dL; 95% CI, −3.57 to
2.28; p = 0.666). After intervention, a significant decrease in fasting glucose level (WMD, −4.16 mg/dL;
95% CI, −6.92 to −1.40; p = 0.003) was confirmed (Figure 3).
An IFD was also associated with lowered HOMA-IR. A total of six studies reported on the
effectiveness of an IFD to reduce HOMA-IR levels. The HOMA-IR levels of the participants were lower
in the IFD group by 0.54 (95% CI, −1.05 to −0.03; p = 0.038) after diet intervention (Figure 4).
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Figure 3. Effect of IF versus non-fasting control on fasting blood glucose (changes from baseline) in
adults without chronic metabolic disease.
Figure 4. Effect of IF versus non-fasting control on homeostatic model assessment of insulin resistance
(HOMA-IR) (changes from baseline) in adults without chronic metabolic disease
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3.4. Effect of Intermittent Fasting on Lean and Fat Mass and Circulating Leptin and Adiponectin
Lean mass did not show significant differences between the two groups, both in the baseline
(WMD, −1.11 kg; 95% CI, −2.62 to 0.41; p = 0.153) and after diet intervention (WMD, −1.26 kg; 95% CI,
−2.78 to 0.26; p = 0.105; Supplementary Figure S2). Although without statistical significance, an IFD
was associated with a trend towards reducing fat mass. The fat mass was higher in the IFD group at
baseline (WMD, 0.37 kg; 95% CI, −0.99 to 1.72; p = 0.596), however, it was lower after intervention
(WMD, −0.98; 95% CI, −2.32 to 0.36; p = 0.151; Supplementary Figure S3).
Although there was no significant change in fat mass after an IFD, an IFD was associated
with an increase in adiponectin level (WMD, 1008.87 ng/mL; 95% CI, 140.45 to 1877.29; p = 0.023;
Supplementary Figure S4) and a decrease in leptin level (WMD, −0.51 ng/mL; 95% CI, −0.77 to −0.24;
p < 0.001; Supplementary Figure S5) without the difference in the baseline.
4. Discussion
The gold standard management of obesity or overweight is 20% to 30% CR along with a
comprehensive lifestyle modification [31], however, rebound weight gain is a real problem of weight
reduction management in clinical situations. Recently, an IFD has been gaining popularity as an
alternative strategy for achieving and maintaining weight reduction. Considering the discrepancy of
IFD effectiveness on glucose metabolism and the lack of evidence in meta-analyses, we conducted
a systematic search and selected 12 studies. On the basis of this meta-analysis, we confirmed
an improvement of fasting blood glucose and insulin resistance through IFD as compared with a
non-fasting control group. This seems to be related to a decrease in the BMI and a leptin level reduction,
as well as an increase in adiponectin level. Lean mass was relatively conserved in the IFD group,
however, no significant weight reduction was identified. In previous studies, the overall weight
reduction of both an IFD and a daily CR (by 15% to 60% of the usual caloric intake every day) were
similar between two groups [32]. In this study, the analysis of total body weight included an additional
paper with higher degree of continuous CR diet as a control group, which explains why there was a
statistically different discrepancy between total body weight and BMI in this study.
With respect to IFD effectiveness on glucose metabolism, many challenges remain. In some
previous studies, the effect of IFD on blood glucose was not significant [33], and there were different
findings according to the characteristics of participants. A 3% to 6% decrease in fasting glucose
was observed in patients with prediabetes [30,34], whereas no significant effect on fasting glucose
concentration was observed in healthy individuals [7]. In this study, we included all studies of
participants with or without prediabetes, because the definition of prediabetes was often unclear in
previous studies. As a result, we found an improvement in blood glucose (fasting glucose level; WMD,
−4.16 mg/dL; 95% CI, −6.92 to −1.40; p = 0.003) and insulin resistance (HOMA-IR; WMD, −0.54; 95% CI,
−1.05 to −0.03; p = 0.038) in the general population with the inclusion of some obese with prediabetes
population groups. Insulin resistance is associated with DM development [35]. Therefore, IFD might
be more beneficial to patients with high insulin resistance who are likely to progress to DM.
The beneficial effects of an IFD including effects on glucose metabolism are often regarded to be
driven by reductions in body weight and/or body fat [5]. Previous IFD studies that adopted ADMF or
ADF diet intervention with a relatively high degree of CR resulted in clinically meaningful reductions
in body weight [6,7], whereas a relatively small (<5.0 kg) weight reduction was achieved in IFD studies
adopting a TRF diet with small degree of CR [21,25]. In addition, no significant weight loss was
observed in studies that adjusted the fasting time while maintaining the total calorie intake [17]. Thus,
the main pathophysiologic mechanism of weight loss through an IFD is likely to be a reduction in the
total calories consumed. In this study, no significant weight loss was observed in the IFD group as
compared to the non-fasting control group. The main explanation for this result might be the mixed
characteristics of the control group including both continuous CR and RD groups. Nevertheless,
a tendency toward weight reduction was observed in the IFD group (WMD, −1.94 kg; 95% CI −5.20 to
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1.31; p = 0.241), and a significant decrease was observed in the analysis with BMI (WMD, −0.75 kg/m2;
95% CI, −1.44 to −0.06; p = 0.033).
Approximately one-fourth to one-third of weight reduction is known to be of lean tissue during
continuous CR, however, lean mass has been preserved in most previous studies under an IF diet
intervention [25]. Similarly, in this study, lean mass did not show a significant difference before
(WMD, −1.11 kg; 95% CI, −2.62 to 0.41; p = 0.153) and after (WMD, −1.26 kg; 95% CI, −2.78 to 0.26;
p = 0.105) the diet intervention. Balancing maximizing loss of body fat and minimizing loss of lean
mass is one of the important pathophysiologic approaches to maintaining physical function and
reducing insulin resistance. The conservation of lean mass may have contributed to the maximization
of HOMA-IR reduction.
Although fat mass reduction during an IFD was not statistically significant (at baseline WMD,
0.37 kg; 95% CI, −0.99 to 1.72; p = 0.596, after intervention WMD, −0.98; 95% CI, −2.32 to 0.36;
p = 0.151), a significant increase in adiponectin level (WMD, 1008.87 ng/mL; 95% CI, 140.45 to 1877.29;
p = 0.023) and a decrease in leptin level (WMD, −0.51 ng/mL; 95% CI, −0.77 to −0.24; p < 0.001)
were observed. Leptin and adiponectin are adipose tissue derived hormones and are associated with
glucose metabolism. Lower leptin concentrations are generally accompanied by a reduction of fat
mass [36]. Adiponectin levels are negatively correlated with insulin resistance, fat mass, and central fat
distribution [37], and based on this analysis, we suggest that an IFD seems to be associated with an
improved distribution of central fat.
Considering the merits of an IFD and its mechanism of different results as compared to continuous
CR, attention has been given to the importance of the fasting time duration in previous studies. After
12 hours of fasting, lipolysis starts in fat tissue and then shifts metabolism from fat storage and lipid
synthesis to mobilization of fat as a form of fatty acid-derived ketones [5]. This can be expected
to reduce fat mass and improve insulin resistance. With similar calorie intake reductions during
continuous CR, this difference in fasting time affects the mass and distribution of fat tissue, finally
making a difference in glucose metabolism, as well as adipokine level changes. In addition, as an
expected advantage of IFD in comparison to continuous CR, an IFD can be sustained with higher
compliance and could have a more significant effect on fat mass reduction and insulin resistance
throughout the fasting period.
The association of circadian rhythm with an IFD is an important issue. In a recent study, increased
risk of cardiovascular disease was reported in a population without or with only a simple breakfast [38].
Skipping breakfast is associated with an increase in the release of stress hormones [39]. In addition, there
was a study showing that significantly improved weight loss and improved insulin resistance were
observed in a group that consumed more calories in the morning and less in the evening, in conditions
with the similar calorie restriction [40]. The type of interventions in the studies included in this analysis
were quite diverse, and there was a limitation to further analysis. Randomized controlled trials under
refined conditions could be helpful to clarify the association with circadian rhythm.
This study had some other limitations. First, only studies that presented the mean and standard
deviation of the baseline and final results with a control group were selected. For this reason,
the number of participants included in the analysis was small. Second, we only included the general
population without chronic metabolic disease, and therefore we could not determine through this
analysis whether an IFD is effective in patients with chronic metabolic disease such as diabetes mellitus.
The intervention group included various types of IF, and the degree of calorie restriction varied
accordingly. The non-fasting control groups also ranged from RD to continuous CR. Despite this
diversity, the subgroup analysis was limited due to the insufficient number of studies. With respect
to the geometric features of participants, including ethnicity, several studies showed heterogeneous
characteristics and others did not provided sufficient information, and therefore we could not conduct
further analysis. Third, since the selected studies all had interventions of short-term (four to 24 weeks)
duration, it is limited to expect long-term effects of IFD.
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In some respects, these limitations may serve as strengths. This study was conducted to analyze
only refined studies with a control group. The participants of this study represent the general population
with a wide range of BMI, and therefore confirm the IF effectiveness on general population without
chronic metabolic disease. Through this study, we found that IF improves glucose metabolism through
lipolysis by confirming the difference in BMI, HOMA-IR, leptin level, and adiponectin concentration
among the participants. Through the results of this analysis, we can expect an improvement of fat
distribution during an IFD, however, further studies are required to clarify this benefit of IFD.
In conclusion, IF significantly improves glycemic control and insulin resistance with a reduction in
BMI, a decrease in leptin level, and an increase in adiponectin concentration in the general population
without chronic metabolic disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/10/1645/s1,
Figure S1: Effect of IF versus non-fasting control on body weight (changes from baseline) in adults without
chronic metabolic disease, Figure S2: Effect of IF versus non-fasting control on lean mass (changes from baseline)
in adults without chronic metabolic disease, Figure S3: Effect of IF versus non-fasting control on fat mass
(changes from baseline) in adults without chronic metabolic disease, Figure S4: Effect of IF versus non-fasting
control on adiponectin level (changes from baseline) in adults without chronic metabolic disease; and Figure S5:
Effect of IF versus non-fasting control on leptin concentration (changes from baseline) in adults without chronic
metabolic disease.
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